NCT05979948 2023-09-14
CZ-WM01
Shanghai Changzheng Hospital
Phase 2 Unknown
Clinical Trials
10 trialsNCT05287984 2022-03-31
ZFCR/ZBR
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Unknown
NCT04934930 2021-06-22
FLMRD
Meir Medical Center
Phase 2 Unknown
NCT02747732 2019-04-23
Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL
Sheba Medical Center
Phase 2 Unknown
NCT03315520 2018-05-22
BeEAC-1
State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia
Phase 2 Unknown
NCT02836639 2016-07-19
BEB Conditioning Regimen for Autologous Stem-cell Transplantation(ASCT) in Non-Hodgkin's Lymphoma
Pusan National University Hospital
Phase 2 Unknown
NCT02758925 2016-05-04
CyBeR-Lymph
University Hospital, Caen
Phase 2 Unknown
NCT02753062 2016-04-27
PTLD
Asan Medical Center
Phase 2 Unknown
NCT01884441 2014-01-29
Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients
Istituto Clinico Humanitas
Phase 2 Unknown
NCT00385125 2006-10-06
Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL
University of Magdeburg
Phase 2 Unknown